composition, not a prescription
KLOW peptide dosage, in research context only
There is no validated human dose for the blend. There is a canonical vial composition and a set of component research doses that do not add up into one number.
The short version
There is no proven human KLOW peptide dosage. No one has run a dosing study on the blend, so any number you see is not validated.
What does exist is a standard research-vial recipe: 80 mg total, split GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg. That is a composition — what is in the vial — not a dose to take.
Here is the catch. The four peptides leave the body at very different speeds. BPC-157 clears in under about half an hour; the two small tripeptides clear even faster. So one shared dose can never keep all four at the same level at once. The component research doses also differ wildly by animal and method — they cannot be added together into a single "KLOW dose." Everything below describes what was studied, in research handling, never a human-use instruction.
Doses Used in the Component Research
Component research doses differ widely by species and route and are not additive into a single number. In rats, BPC-157 was given at 400 and 800 ng/kg in the gastric-ulcer model [4], and at 10 microg, 10 ng or 10 pg per rat once daily in the transected-tendon model [5]. Thymosin beta-4 was active in keratinocyte-migration assays at as little as 10 pg, with wound studies using topical and intraperitoneal delivery [6]. KPV worked at 10 nM in vitro and 100 uM in drinking water in mice [2]. GHK-Cu acts at nanomolar concentrations in vitro and in topical formulations clinically [7].
These are single-component doses, in single-component studies. No study established a dose for the four-peptide blend, and the component numbers above cannot be summed into a "KLOW dose" [1].
What Is in the 80 mg Research Vial
The canonical research vial is 80 mg total: GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg. GHK-Cu is mass-dominant at roughly 62.5% of the vial; the other three split the remaining 30 mg evenly.
The four are co-dissolved at fixed mass ratios but remain four separate molecules — the vial is a mixture, not a compound [1]. No FDA-approved or pharmacopeial KLOW combination product exists; the vial is a research-chemical co-formulation.
How the Research Vial Is Reconstituted and Handled
The lyophilized (freeze-dried) blend is reconstituted with bacteriostatic water for laboratory handling, and the resulting solution is typically refrigerated. This describes research handling, not a human-use protocol.
A chemistry note specific to this blend: the copper(II) in GHK-Cu can participate in redox chemistry, a theoretical compatibility consideration when it is co-dissolved with the other three peptides in one vial. That interaction has not been formally characterized for this mixture [12]. The reconstituted solution's blue-to-teal tint comes from the chelated copper(II) of GHK-Cu — a property of the copper peptide, not a defect [7].
The pharmacokinetic mismatch within one vial
The four peptides have markedly different reported half-lives. BPC-157 has a very short elimination half-life — under about 30 minutes in the formal pharmacokinetic study, with rapid breakdown into small peptide fragments [9]. The two tripeptides, KPV and GHK-Cu, clear even faster, and the TB-500 fragment behaves differently from native thymosin beta-4.
The consequence is structural: a single co-formulated dose cannot hold all four components at matched exposures. Whatever schedule keeps one peptide present leaves another already cleared. This is one reason the blend's behavior cannot simply be read off the four single-component literatures [1].
What route did the component research use?
Component research most commonly used subcutaneous injection for research handling. The broader single-component literature also covers topical delivery (GHK-Cu) [7], oral and targeted delivery (KPV, BPC-157) [2][4], and intra-articular injection (BPC-157). This describes the routes studied for the individual peptides, not a human-use instruction for the blend.
How much KLOW peptide per day?
There is no validated human daily amount for the blend. The canonical research vial holds 80 mg total across four peptides (GHK-Cu 50 + BPC-157 10 + TB-500 10 + KPV 10), but component research doses differ widely by species and route and are not additive into a single "KLOW dose" [1]. This describes vial composition, not a dose to take.
How often is it administered in research?
There is no established human frequency for the blend. The pharmacokinetic mismatch makes a single schedule impossible to optimize: BPC-157 has a very short elimination half-life — under about 30 minutes in the formal study — and the tripeptides clear even faster, so no one schedule keeps all four at matched exposures [9][1].
How is the KLOW research vial reconstituted?
The lyophilized blend is reconstituted with bacteriostatic water for laboratory handling, and the solution is typically refrigerated. The copper(II) in GHK-Cu can participate in redox chemistry, a theoretical compatibility consideration when it is co-dissolved with the other three peptides — one that has not been formally characterized for this mixture [12].
What is the KLOW peptide dosage?
No human dosing has been validated for the blend. The canonical research vial is 80 mg total = GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg, reconstituted with bacteriostatic water for laboratory handling [1]. This is composition, not a recommended dose.
What is the KLOW peptide dosage and frequency?
Neither a dose nor a frequency is established for the blend in humans. Because the components have markedly different half-lives — fast-clearing KPV and GHK-Cu against the longer BPC-157, and the TB-500 fragment against native thymosin beta-4 — no single schedule keeps all four at matched exposures [9][1]. That is the pharmacokinetic-mismatch problem.
How many mg of KLOW peptide per day?
No validated per-day milligram amount exists for the blend. The full canonical vial holds 80 mg total across four peptides, but component research doses are not additive and there is no human dosing study for KLOW [1]. This describes vial composition, not a dose to take.